Tags

Type your tag names separated by a space and hit enter

Lurasidone for the treatment of irritability and anger in autism spectrum disorders.
Expert Opin Investig Drugs. 2017 Aug; 26(8):985-989.EO

Abstract

INTRODUCTION

Autism Spectrum Disorder (ASD) is a heterogeneous neurodevelopmental disorder characterized by deficits in social interaction and communication as well as restricted patterns of behaviors and interests. Irritability marked by tantrums, self-injury and aggression occurs frequently in youth with ASD, causing significant parent and caregiver distress. Atypical antipsychotics have been the most studied drug class targeting irritability in ASD. Risperidone and aripiprazole are Food and Drug Administration (FDA)-approved atypical antipsychotics for treatment of irritability in youth with ASD. However, other atypical antipsychotics, such as lurasidone, are often considered for off-label use in the treatment of irritability, whether because of tolerability issues with risperidone and aripiprazole or because of the drug-refractory nature of this symptom cluster. Areas covered: Following a comprehensive review of the literature this article summarizes information on the efficacy and tolerability of lurasidone as a potential off label treatment of irritability in children and adolescents with ASD. Available data included a 6 week randomized, blind, fixed dose, placebo-controlled study and a case study. Expert opinion: To date the safety and tolerability of lurasidone in treating irritability in youth with ASD has yet to be established with, lurasidone being the only antipsychotic with published negative placebo-controlled results.

Authors+Show Affiliations

a Division of Child and Adolescent Psychiatry , Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA.a Division of Child and Adolescent Psychiatry , Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA.a Division of Child and Adolescent Psychiatry , Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA.a Division of Child and Adolescent Psychiatry , Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA.a Division of Child and Adolescent Psychiatry , Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28685626

Citation

McClellan, Lynn, et al. "Lurasidone for the Treatment of Irritability and Anger in Autism Spectrum Disorders." Expert Opinion On Investigational Drugs, vol. 26, no. 8, 2017, pp. 985-989.
McClellan L, Dominick KC, Pedapati EV, et al. Lurasidone for the treatment of irritability and anger in autism spectrum disorders. Expert Opin Investig Drugs. 2017;26(8):985-989.
McClellan, L., Dominick, K. C., Pedapati, E. V., Wink, L. K., & Erickson, C. A. (2017). Lurasidone for the treatment of irritability and anger in autism spectrum disorders. Expert Opinion On Investigational Drugs, 26(8), 985-989. https://doi.org/10.1080/13543784.2017.1353600
McClellan L, et al. Lurasidone for the Treatment of Irritability and Anger in Autism Spectrum Disorders. Expert Opin Investig Drugs. 2017;26(8):985-989. PubMed PMID: 28685626.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lurasidone for the treatment of irritability and anger in autism spectrum disorders. AU - McClellan,Lynn, AU - Dominick,Kelli C, AU - Pedapati,Ernest V, AU - Wink,Logan K, AU - Erickson,Craig A, Y1 - 2017/07/24/ PY - 2017/7/8/pubmed PY - 2017/8/8/medline PY - 2017/7/8/entrez KW - Autism KW - adolescent KW - anger KW - atypical antipsychotics KW - children KW - irritability KW - lurasidone SP - 985 EP - 989 JF - Expert opinion on investigational drugs JO - Expert Opin Investig Drugs VL - 26 IS - 8 N2 - INTRODUCTION: Autism Spectrum Disorder (ASD) is a heterogeneous neurodevelopmental disorder characterized by deficits in social interaction and communication as well as restricted patterns of behaviors and interests. Irritability marked by tantrums, self-injury and aggression occurs frequently in youth with ASD, causing significant parent and caregiver distress. Atypical antipsychotics have been the most studied drug class targeting irritability in ASD. Risperidone and aripiprazole are Food and Drug Administration (FDA)-approved atypical antipsychotics for treatment of irritability in youth with ASD. However, other atypical antipsychotics, such as lurasidone, are often considered for off-label use in the treatment of irritability, whether because of tolerability issues with risperidone and aripiprazole or because of the drug-refractory nature of this symptom cluster. Areas covered: Following a comprehensive review of the literature this article summarizes information on the efficacy and tolerability of lurasidone as a potential off label treatment of irritability in children and adolescents with ASD. Available data included a 6 week randomized, blind, fixed dose, placebo-controlled study and a case study. Expert opinion: To date the safety and tolerability of lurasidone in treating irritability in youth with ASD has yet to be established with, lurasidone being the only antipsychotic with published negative placebo-controlled results. SN - 1744-7658 UR - https://www.unboundmedicine.com/medline/citation/28685626/Lurasidone_for_the_treatment_of_irritability_and_anger_in_autism_spectrum_disorders_ L2 - https://www.tandfonline.com/doi/full/10.1080/13543784.2017.1353600 DB - PRIME DP - Unbound Medicine ER -